<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01751919</url>
  </required_header>
  <id_info>
    <org_study_id>Imatinib_CML_I</org_study_id>
    <nct_id>NCT01751919</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)</brief_title>
  <official_title>A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400 mg (1 Tablet) and Glivec Film-coated Tablet 100 mg (4 Tablets) After Oral Administration in Healthy Male Subjects (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Investigational Product

             1. Imatinib mesylate tablet 400 mg

             2. Glivec film-coated tablet 100 mg (Comparator)

        2. Expected target disease

             1. chronic myeloid leukemia

             2. Gastrointestinal stromal tumors

        3. Study design : Randomized, open-label, single dose, two-period, two-way, crossover study

             1. 36 healthy subjects, 2 groups (18 subjects/group)

             2. 2 Period (either 1-a(1 tablet) or 1-b(4 tablet))

             3. wash-out period : 14 days

        4. Evaluation on pharmacokinetics(PKs) and safety

             1. PKs : Cmax, AUClast, Tmax, AUCinf, t1/2

             2. safety : adverse events, physical examination, vital sign, ECG, Laboratory test

        5. Statistical method

             1. Demography Characteristics

             2. Pharmacokinetic parameters

             3. Safety data
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration in plasma (Cmax) of Imatinib mesylate</measure>
    <time_frame>Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from zero time until the last measurable concentration (AUClast) of Imatinib mesylate</measure>
    <time_frame>Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of Imatinib mesylate</measure>
    <time_frame>Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUCinf) of Imatinib mesylate</measure>
    <time_frame>Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2) of Imatinib mesylate</measure>
    <time_frame>Pre-dose(0h) AND 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 48, 72 h post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Group 1 (RT)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)
Period 2: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (TR)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Period 1: Imatinib mesylate tablet 400 mg, 1 tablet (experimental)
Period 2: Glivec film-coated tablet 100 mg, 4 tablets (Active comparator)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib mesylate tablet 400 mg, 1 Tablet</intervention_name>
    <arm_group_label>Group 1 (RT)</arm_group_label>
    <arm_group_label>Group 2 (TR)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec film-coated tablet 100 mg, 4 Tablets</intervention_name>
    <arm_group_label>Group 1 (RT)</arm_group_label>
    <arm_group_label>Group 2 (TR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male volunteers between the ages of 20 to 50 years old

          -  weight more than 55kg and within the range of ±20% of ideal body weight (IBW)

          -  having neither congenital/chronic diseases nor pathological symptoms/findings as
             results of medical examination

          -  doctor determines to be suitable as subjects within 3 weeks ago before administration

        Exclusion Criteria:

          -  Hypersensitivity(or history of hypersensitivity) to medicines including imatinib
             mesylate

          -  Active Liver Diseases or exceed 1.5 times the normal range of AST, ALT, total
             bilirubin

          -  Creatinine clearance &lt; 80 mL/min

          -  Gastrointestinal diseases or surgeries that affect absorption of drug

          -  Excessive drinking(exceed 21units/week)

          -  Smoking over 10 cigarettes per day
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyungpook National University</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodríguez P, Márquez S, Guarneri C, Estevez-Parrillo FT, Laurenz M, Estevez-Carrizo FE. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther. 2009 Oct;31(10):2224-32. doi: 10.1016/j.clinthera.2009.10.009.</citation>
    <PMID>19922893</PMID>
  </reference>
  <reference>
    <citation>Nikolova Z, Peng B, Hubert M, Sieberling M, Keller U, Ho YY, Schran H, Capdeville R. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol. 2004 May;53(5):433-8.</citation>
    <PMID>15132131</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2012</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>GIST</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

